Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Operating Leases (2021 - 2025)

Pliant Therapeutics (PLRX) has disclosed Operating Leases for 5 consecutive years, with $29.1 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 1.13% to $29.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.1 million through Dec 2025, down 1.13% year-over-year, with the annual reading at $29.1 million for FY2025, 1.13% down from the prior year.
  • Operating Leases for Q4 2025 was $29.1 million at Pliant Therapeutics, down from $29.4 million in the prior quarter.
  • The five-year high for Operating Leases was $29.9 million in Q1 2025, with the low at $2.3 million in Q2 2023.
  • Average Operating Leases over 5 years is $15.7 million, with a median of $6.9 million recorded in 2022.
  • The sharpest move saw Operating Leases tumbled 58.81% in 2023, then skyrocketed 731.58% in 2024.
  • Over 5 years, Operating Leases stood at $5.3 million in 2021, then plummeted by 35.61% to $3.4 million in 2022, then plummeted by 32.4% to $2.3 million in 2023, then skyrocketed by 1170.02% to $29.4 million in 2024, then decreased by 1.13% to $29.1 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $29.1 million, $29.4 million, and $28.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.